These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 17523848

  • 1. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ, Yang S, Pruijn FB, Pullen SM, Hogg A, Patterson AV, Wilson WR, Denny WA.
    J Med Chem; 2007 Mar 22; 50(6):1197-212. PubMed ID: 17326614
    [Abstract] [Full Text] [Related]

  • 3. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):560-71. PubMed ID: 17869669
    [Abstract] [Full Text] [Related]

  • 4. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
    Helsby NA, Wheeler SJ, Pruijn FB, Palmer BD, Yang S, Denny WA, Wilson WR.
    Chem Res Toxicol; 2003 Apr 01; 16(4):469-78. PubMed ID: 12703963
    [Abstract] [Full Text] [Related]

  • 5. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
    Helsby NA, Atwell GJ, Yang S, Palmer BD, Anderson RF, Pullen SM, Ferry DM, Hogg A, Wilson WR, Denny WA.
    J Med Chem; 2004 Jun 03; 47(12):3295-307. PubMed ID: 15163209
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP, Anderson RF, Ferry DM, Wilson WR, Denny WA.
    J Med Chem; 2003 Dec 04; 46(25):5533-45. PubMed ID: 14640560
    [Abstract] [Full Text] [Related]

  • 7. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J, Oleschuk CJ, Guziec F, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.
    Cancer Chemother Pharmacol; 2002 Feb 04; 49(2):101-10. PubMed ID: 11862423
    [Abstract] [Full Text] [Related]

  • 8. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
    Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA.
    Cancer Res; 2002 Mar 01; 62(5):1425-32. PubMed ID: 11888915
    [Abstract] [Full Text] [Related]

  • 9. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
    Günther M, Waxman DJ, Wagner E, Ogris M.
    Cancer Gene Ther; 2006 Aug 01; 13(8):771-9. PubMed ID: 16543915
    [Abstract] [Full Text] [Related]

  • 10. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
    Wilson WR, Tercel M, Anderson RF, Denny WA.
    Anticancer Drug Des; 1998 Sep 01; 13(6):663-85. PubMed ID: 9755724
    [Abstract] [Full Text] [Related]

  • 11. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
    Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV.
    Biochem Pharmacol; 2007 Sep 15; 74(6):810-20. PubMed ID: 17645874
    [Abstract] [Full Text] [Related]

  • 12. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
    Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR.
    Cancer Res; 2009 May 01; 69(9):3884-91. PubMed ID: 19366798
    [Abstract] [Full Text] [Related]

  • 13. Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro.
    Chen JK, Hu LJ, Wang D, Lamborn KR, Deen DF.
    Int J Radiat Oncol Biol Phys; 2007 Apr 01; 67(5):1538-47. PubMed ID: 17394949
    [Abstract] [Full Text] [Related]

  • 14. Bystander effects induced by continuous low-dose-rate 125I seeds potentiate the killing action of irradiation on human lung cancer cells in vitro.
    Chen HH, Jia RF, Yu L, Zhao MJ, Shao CL, Cheng WY.
    Int J Radiat Oncol Biol Phys; 2008 Dec 01; 72(5):1560-6. PubMed ID: 19028278
    [Abstract] [Full Text] [Related]

  • 15. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
    Tercel M, Atwell GJ, Yang S, Stevenson RJ, Botting KJ, Boyd M, Smith E, Anderson RF, Denny WA, Wilson WR, Pruijn FB.
    J Med Chem; 2009 Nov 26; 52(22):7258-72. PubMed ID: 19877646
    [Abstract] [Full Text] [Related]

  • 16. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P, Waxman DJ.
    Toxicol In Vitro; 2006 Mar 26; 20(2):176-86. PubMed ID: 16293390
    [Abstract] [Full Text] [Related]

  • 17. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.
    Hay MP, Wilson WR, Denny WA.
    Bioorg Med Chem; 2005 Jun 02; 13(12):4043-55. PubMed ID: 15911317
    [Abstract] [Full Text] [Related]

  • 18. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
    De Ridder M, Van Esch G, Engels B, Verovski V, Storme G.
    Bull Cancer; 2008 Mar 02; 95(3):282-91. PubMed ID: 18390408
    [Abstract] [Full Text] [Related]

  • 19. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV.
    Cancer Res; 2010 Feb 15; 70(4):1573-84. PubMed ID: 20145130
    [Abstract] [Full Text] [Related]

  • 20. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
    Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson WR, Patterson AV.
    Cancer Gene Ther; 2007 Dec 15; 14(12):953-67. PubMed ID: 17975564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.